Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines

Keyphrases

• Tumor Cell Lines 100%
• Rhabdoid Tumor 100%
• Anticancer Agents 100%
• Antiproliferative Effect 100%
• Enhancer of Zeste Homolog 2 (EZH2) 71%
• 5-aza-2′-deoxycytidine 71%
• 3-deazaneplanocin A 71%
• Suberoylanilide Hydroxamic Acid 71%
• Epigenetics 28%
• New Therapeutic Approaches 28%
• Pharmacological Inhibitors 28%
• Etoposide 28%
• Antitumor Activity 28%
• Sequential Treatment 28%
• Active Pharmaceutical Ingredients 28%
• Therapeutic Target 14%
• Treatment Protocol 14%
• Pediatric Malignancy 14%
• In Cancer 14%
• In Vivo Analysis 14%
• Tumor Cells 14%
• Apoptosis 14%
• Poor Prognosis 14%
• Cell Growth 14%
• Cell Cycle Progression 14%
• Functional Analysis 14%
• Anticancer Drugs 14%
• Apoptotic Cells 14%
• Histone Demethylase 14%
• Microarray Analysis 14%
• Epigenetic Silencing 14%
• Global Gene Expression 14%
• S-adenosylhomocysteine 14%
• Highly Aggressive 14%
• Stem Cell Maintenance 14%
• Antiproliferative Activity 14%
• Neuronal Development 14%
• Metabolic Processes 14%
• Cytostatic Drugs 14%
• Clonogenicity 14%
• Combinational Therapy 14%
• Cell Proliferation Assay 14%
• Therapeutic Optimization 14%
• Hydrolase Inhibitors 14%
• Doxorubicin Drug 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Rhabdoid Tumor 100%
• Anticarcinogen 100%
• Vorinostat 71%
• Transcription Factor EZH2 71%
• 3-Deazaneplanocin A 71%
• Etoposide 28%
• Antitumor Activity 28%
• Malignant Neoplasm 14%
• Childhood Cancer 14%
• Doxorubicin 14%
• Histone Methyltransferase 14%
• Homocysteine 14%
• Cytostatic Agent 14%
• Antiproliferative Activity 14%
• Antibiotic A204 14%
• Hydrolase Inhibitor 14%